News
Fairtility unveils CHLOE OQ™ expanding its offering into fertility preservation
CHLOE OQ™ secures CE, empowering embryologists and patients with oocyte quality insights for egg freezing, egg donation and IVF applications

Fairtility, the transparent AI innovator powering reproductive care for improved outcomes, has announced the launch of CHLOE OQ™, bringing Oocyte Quality Insights to CHLOE’s core technology suite of capabilities and expanding the applicability of its AI-driven decision support tool to fertility preservation.
The solution will be unveiled at the 39th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) being held in Copenhagen, Denmark from June 25 to 28, 2023.
With CE declared for CHLOE OQ™, the new Oocyte Quality Insights capability offers IVF professionals comprehensive information to support decision making as patients undergo fertility preservation or assisted reproductive journeys.
The tool delivers predictions of an oocyte’s potential to reach the blastocyst stage post-fertilisation.
“Assessing fertility potential involves understanding three factors: sperm, oocytes and embryos. We can evaluate the viability of embryos and understand sperm quality. However, assessing oocyte quality has remained a statistical gamble,” said Dr Cristina Hickman, chief clinical officer of Fairtility.
“When looking at a seemingly ‘good’ oocyte, we can’t really identify which one will become a blast after fertilisation. CHLOE OQ helps us fill the critical gap, providing evidence-based viability predictions for the evaluation of oocytes.
“This will help clinicians to provide transparency to patients while discussing a failed IVF cycle in fertility preservation, or when assessing and allocating donor eggs.”
Oocyte quality assessment commonly relies on statistical methods based on a woman’s age. Embryologists analyse oocyte quality based on oocyte maturity and characteristics including size, texture, shape, discoloration and fragmentation.
However, these factors have proven to be subjective and lack correlation with the actual quality of the egg.
CHLOE OQ brings the power of AI to oocyte assessment, replacing generalised decision-making with personalised, data-driven AI analysis that reveals the potential of each oocyte backed by biological data.
CHLOE OQ offers personalised data to support decision making for three key applications:
- Egg freezing: In the process of fertility preservation, IVF professionals may recommend an additional oocyte retrieval based on the raw number of oocytes retrieved. While CHLOE OQ cannot change the biology of the egg, it can assist in providing a personalised assessment and managing expectations for family planning early on. CHLOE OQ helps IVF professionals and patients make informed decisions on whether to undergo an additional oocyte retrieval cycle. The tool is designed to optimise the chances of successful IVF in the future and gives women greater control of their reproductive opportunities later in life.
- Egg donation: CHLOE OQ helps fertility clinics and egg banks to further assess the quality of donor eggs, ensuring equitable distribution to recipients. By leveraging data-driven insights, donor-egg providers may match recipients with the most suitable donor eggs, increasing the chances of successful IVF outcomes, maximising limited donor egg resources and enhancing the donor-recipient experience.
- IVF treatment: During IVF, older patients are often guided to utilise donor eggs based on age rather than the true quality of their eggs. At 40-years of age, approximately 10 per cent of patients utilise their own eggs, and by 44-years old, this number drops to one per cent. CHLOE OQ is expected to help IVF professionals consider if a patient’s own eggs have sufficient quality for a successful IVF treatment, or if an egg donor may be a more suitable option. This reduces costs for patients undergoing IVF and maximises egg donor resources. A better understanding of oocyte quality also provides IVF professionals insight on an oocyte’s role in a failed IVF cycle, enabling better treatment decisions for future IVF cycles.
“Adding oocyte analysis broadens CHLOE’s core technology capabilities, extending beyond embryo assessment for IVF. CHLOE OQ now provides decision support for fertility preservation, egg donation, and female-factor infertility in IVF treatment. This expansion allows us to assist a larger population seeking to secure their reproductive futures,” stated Eran Eshed, CEO and co-Founder of Fairtility.
“While we can’t halt the passage of time and the consequent decline in oocyte quality, we can effectively freeze it. With CHLOE OQ, patients, through their fertility care team, can gain transparency into their oocytes’ viability, enabling proactive management of their reproductive health and facilitating well-informed decisions based on biological data.”
CHLOE’s core technology is the first and only decision support tool that combines AI-driven analysis of embryos and oocytes with explainable biological insights in terms that IVF professionals understand and can trust.
This supports data-driven and consistent decision-making in the IVF lab, with a goal of optimising outcomes, making fertility care more efficient and creating new family-building possibilities.

Insight
Benchmarking 2027: Shifting priorities in US health infrastructure

By Women’s HealthX
As healthcare organisations navigate tightening compliance mandates, evolving reimbursement frameworks, and shifting health economics, the single most critical asset for leadership is operational visibility into what their industry counterparts are executing right now.
Ahead of the Women’s HealthX marketplace in Boston this December, a cross-functional steering committee of health plans, hospital networks, biopharma innovators, and enterprise employers has launched the definitive 2026 U.S. Health Infrastructure Survey.
The objective of this brief, multi-state index is to bypass abstract market fluff and map out exactly how the country’s elite healthcare stakeholders are practically structuring their 2027 budgets, clinical protocols, and technology procurement guidelines.
Some of the questions we are asking:
- Health Plans & Payers “What is the biggest operational barrier to expanding women’s health coverage?”
- Health Systems & Providers “What is the biggest women’s health priority for health systems over the next 24 months?”
- Pharma & Life Sciences “What is the biggest commercial hurdle facing women’s health innovation?”
- Employers & Benefits Leaders “Which women’s health challenge creates the greatest workforce impact?”
By contributing just 60 seconds of your operational insight to the index, you will ensure your specific sector’s parameters are accurately represented.
In return for your participation, you will secure a priority, pre-ordered copy of the completed 30-page intelligence report when the final data drops this September!
See where your direct peer groups are drawing their line in the sand for the upcoming fiscal year.
Contribute 60 seconds and pre-order your national benchmark report
Women’s HealthX 2026 | From Rhetoric to Results
Encore Boston Harbor | December 3-4 2026
Bypass abstract market rhetoric to evaluate real-world health economics, regulatory compliance mandates, and care delivery systems.
Join the region’s foremost health plan medical directors, hospital COOs, biopharma innovators, and enterprise benefits buyers anchoring our 2026 tracks.
Opinion
Why health AI needs to read between the lines

Sahar Abid is a Science Associate at Ema EQ, where she works on cultural sensitivity and bias in AI.
A woman asks an AI health assistant about postpartum depression.
She mentions that her in-laws are telling her to “push through” and skip medical help, even as her symptoms get harder to manage. She never says where she is from or names her background.
The assistant describes the condition and gives her a hotline number. It sounds correct, but it misses what she needs.
That gap is more common than the industry admits, and it points to a blind spot in how we test health AI for bias.
Most bias testing looks at what people explicitly say.
The typical way to check an AI for bias is to label a prompt with someone’s demographic details and see if the answer changes. That catches some problems but misses a bigger one.
Most people do not lead with their identity. They lead with their situation. The woman above told the assistant everything it needed to help her, just not in the form of a label.
Her real question was not only “what is postpartum depression?” It was “how do I get care when the people around me don’t want me to?
When family members hold sway over health decisions, and in many communities they do, advice that asks someone to overrule their family is not something they can act on.
The AI didn’t say anything factually wrong. It answered a different question than the one she was living.
We call this culturally implicit bias, meaning the AI misses the cultural context a situation implies rather than the context a person spells out.
When systems are trained to notice only the explicit cues, they fall back on a default answer built for the majority. For everyone else, the response can feel generic, off-target, or discouraging enough that they stop looking for help.
In health, that is not small. The people most likely to be missed are often the ones the system already underserves.
What we set out to test.
At Ema, we wanted to know how well AI picks up on cultural context that is implied but never stated. So we built our own way to test for it, across a range of communities and real situations like postpartum depression and fertility, using questions that carried cultural meaning without announcing it.
The patterns were consistent. Models often missed the meaning underneath the question. They dropped the specific details a person did share and smoothed them into something generic.
And even when they pointed toward real care, they tended to offer one option instead of choices that might actually fit a person’s life. Any one of those can be the difference between someone following the advice and walking away from care.
Why this matters for anyone building health AI.
Getting this right is the right thing to do, and it also works better.
When an answer reflects a person’s real context, people trust and act on the recommendations more, so they get the help and support they need.
Testing for it is harder than the shortcut most teams use. Swapping a name or a demographic label in and out is easy. Checking whether a model actually understands the human context around a question takes more care.
The shortcut teaches models to perform cultural competence instead of practicing it. No matter how much or how little someone chooses to share, they deserve an answer that is warm, complete, and usable.
A better question.
The bar for equitable health AI should be “does it serve someone who never told you who they are?” It is the harder test, but it determines whether real people get help.
The work of getting there is far from finished, and it is exactly what we are building toward at Ema.
Sources: Naidoo, V., & Chadha, K. K. (2025), Culturally responsive AI chatbots: from framework to field evidence, Computers in Human Behavior: Artificial Humans. Souligne, N., & Subbian, V. (2026), FairLogue: A toolkit for intersectional fairness analysis in clinical machine learning models.
News
Women drove 71% of global health workforce growth since 1990 – study

Women accounted for 71.4 per cent of global health workforce growth between 1990 and 2023, according to a study covering 204 countries and territories.
The global workforce almost tripled over the period, rising from 40.9m to 122.1m workers.
Women represented 68.9 per cent of all health workers in 2023, but remained concentrated in professions that generally offer lower pay and fewer leadership opportunities.
The study analysed 20 groups of specially trained health personnel, including doctors, nurses, midwives, pharmacists, dentists and community health workers.
Between 1990 and 2023, the workforce grew by more than 81m people, including an additional 18.9m nurses and 8.7m doctors.
In 2023, there were 33.2m nurses, 15.1m doctors, 7.6m community health workers, 6.8m pharmacists and pharmaceutical assistants, and 6.1m dentists and dental assistants worldwide.
Women made up 80.7 per cent of nurses, 96 per cent of midwives and 89.5 per cent of community health workers, while fewer than half of doctors were women.
A similar pattern was seen in dentistry and pharmacy, where women were more likely to work as assistants than as dentists or pharmacists.
Megan Knight, lead author of the study and researcher at the Institute for Health Metrics and Evaluation, said: “Women have transformed the global health workforce over the past three decades, but they continue to be concentrated in professions that generally offer lower pay and fewer opportunities for leadership.
“Building stronger health systems will require not only expanding the workforce, but also creating equitable opportunities for career advancement, leadership, and safe, supportive working environments.”
Despite the growth, researchers estimated that an additional 34.4m doctors, nurses, midwives, dentists and pharmacists would be needed to achieve moderate levels of universal health coverage.
Universal health coverage means people can access essential health services without experiencing financial hardship.
The estimated global shortage includes 23.9m nurses and midwives, 7.1m doctors, 1.8m dentists and 1.6m pharmacists.
South Asia had the largest estimated shortages, requiring an additional 2.6m doctors and 10m nurses and midwives to reach the study’s benchmark for moderate universal health coverage.
Sub-Saharan Africa also had substantial shortages. Nursing density was estimated at 14.5 nurses per 10,000 people, compared with 121.8 per 10,000 in high-income countries.
At country level, there were 3.2 nurses per 10,000 people in Chad and 3.3 in Madagascar, compared with 171.7 in Belgium and 161.4 in the US.
Dr Annie Haakenstad, senior author of the study and assistant professor of health metrics sciences at the Institute for Health Metrics and Evaluation, said: “Health workers are the foundation of every health system.
“Although the global workforce has expanded dramatically, millions more doctors, nurses, midwives, dentists, and pharmacists will be needed to ensure people everywhere can access essential health services.
“These findings provide countries with minimum thresholds for planning the workforce needed to strengthen health systems and move toward universal health coverage.”
The study estimated that moderate universal health coverage was associated with minimum workforce densities of 23.8 doctors and 64.5 nurses and midwives per 10,000 people, alongside 5.2 dentists and 5.6 pharmacists per 10,000.
Researchers said closing workforce gaps would require continued investment in education, recruitment, retention and working conditions.
They also highlighted gender-responsive policies, including leadership development, workplace protections, paid parental leave and flexible work arrangements, as measures that could support a predominantly female workforce.
News2 weeks agoUK femtech investment surges 194% in a decade, research finds
Entrepreneur2 weeks agoTidalSense raises £14m to expand five-minute COPD test across NHS
News2 weeks agoCross-Border Impact Ventures raises US$58m for women and children’s health
Entrepreneur1 week agoApplications close August 18 for Women’s Health Innovation Summit 2026 Innovation Showcase
News2 weeks agoCultural stigma is a barrier to menopause help, black women say
Mental health1 week agoThird of women unaware of perimenopause mental health impact
Hormonal health2 weeks agoMenstrual data is missing a critical layer: The mind
Entrepreneur2 weeks agoWomen’s Health Week Europe 2026 releases fully populated agenda ahead of October summit












Pingback: Fairtility unveils CHLOE OQ™ expanding its offering into fertility preservation - Fairtility
Pingback: Fairtility unveils CHLOE OQ™ expanding its offering into fertility preservation - Fairtility